Citizens Reiterates Market Outperform on Biomea Fusion, Maintains $7 Price Target
Citizens analyst Jonathan Wolleben reiterates Biomea Fusion (NASDAQ:BMEA) with a Market Outperform and maintains $7 price target.
Stocks · News reference
Worthington Enterprises surged 15.9% premarket after beating Q1 EPS and sales estimates; Wheeler REIT led gainers, while Jaguar Health and Biomea fell.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Citizens analyst Jonathan Wolleben reiterates Biomea Fusion (NASDAQ:BMEA) with a Market Outperform and maintains $7 price target.
U.S. futures were mixed. State Street fell 6.4% after missing sales estimates, while Biomea Fusion, Skydance and other stocks slid premarket.
HC Wainwright & Co. analyst Joseph Pantginis reiterates Biomea Fusion (NASDAQ:BMEA) with a Buy and maintains $4 price target.
Enovix jumps 6.8% after securing a 100,000-unit battery order from a multinational drone maker, with deliveries planned for H1 2027.